Insider Transactions in Q3 2023 at Neumora Therapeutics, Inc. (NMRA)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 29
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
34,560
+0.89%
|
$449,280
$13.98 P/Share
|
|
Sep 29
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
34,560
+0.89%
|
$449,280
$13.98 P/Share
|
|
Sep 28
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
41,951
+0.55%
|
$545,363
$13.38 P/Share
|
|
Sep 28
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
41,951
+0.55%
|
$545,363
$13.38 P/Share
|
|
Sep 27
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
24,504
+0.64%
|
$294,048
$12.31 P/Share
|
|
Sep 27
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
24,504
+0.64%
|
$294,048
$12.31 P/Share
|
|
Sep 26
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
34,000
+0.9%
|
$374,000
$11.73 P/Share
|
|
Sep 26
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
34,000
+0.9%
|
$374,000
$11.73 P/Share
|
|
Sep 25
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
60,740
+0.81%
|
$668,140
$11.23 P/Share
|
|
Sep 25
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
60,740
+0.81%
|
$668,140
$11.23 P/Share
|
|
Sep 22
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
40,000
+1.08%
|
$440,000
$11.14 P/Share
|
|
Sep 22
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,000
+1.08%
|
$440,000
$11.14 P/Share
|
|
Sep 19
2023
|
Fmr LLC |
BUY
Conversion of derivative security
|
Indirect |
3,712,624
+35.19%
|
-
|
|
Sep 19
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+29.27%
|
$25,500,000
$17.0 P/Share
|
|
Sep 19
2023
|
Kristina Burow |
BUY
Conversion of derivative security
|
Indirect |
17,424,704
+44.34%
|
-
|
|
Sep 19
2023
|
Kristina Burow |
BUY
Conversion of derivative security
|
Direct |
13,620
+50.0%
|
-
|
|
Sep 19
2023
|
Arch Venture Partners X, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,000,000
+29.27%
|
$51,000,000
$17.0 P/Share
|
|
Sep 19
2023
|
Arch Venture Partners X, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
34,849,408
+44.34%
|
-
|
|
Sep 19
2023
|
Henry O Gosebruch President & CEO |
BUY
Open market or private purchase
|
Indirect |
15,000
+50.0%
|
$180,000
$12.62 P/Share
|
|
Sep 19
2023
|
Amgen Inc |
BUY
Open market or private purchase
|
Direct |
1,764,705
+4.75%
|
$29,999,985
$17.0 P/Share
|
|
Sep 19
2023
|
Amgen Inc |
BUY
Conversion of derivative security
|
Direct |
33,603,948
+50.0%
|
-
|
|
Sep 14
2023
|
Robert A. Lenz Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
352,941
+50.0%
|
-
|